Glycoprotein News and Research

RSS

RNA-binding proteins may suppress antiviral defenses against SARS-CoV-2

Conducted by researchers in South Korea at the Institute for Basic Science and the International Vaccine Institute, a new study published on the preprint server bioRxiv in November 2020 describes the many host proteins that bind with the ribonucleic acid (RNA) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and regulate the replication of the virus.

4 Nov 2020

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.

4 Nov 2020

Evidence of robust and persistent antibodies against SARS-CoV-2

A team of researchers from the Icahn School of Medicine at Mount Sinai, New York, have worked in collaboration to try and answer one of the most baffling questions surrounding the coronavirus disease 19 (COVID-19) pandemic: do antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) last after a primary infection?

3 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

SARS-CoV-2 spike D614G variant exhibits enhanced replication and transmissibility

A team of scientists from Switzerland, Germany, and the USA has demonstrated that the S-614G variant can easily bind to the human angiotensin-converting enzyme 2 (ACE2), the cellular gateway of SARS-CoV-2. The variant also showed enhanced replication and transmissibility in animal models.

2 Nov 2020

SARS-CoV-2 viroporin triggers NLRP3 inflammasome causing a severe inflammatory response

Now, a team of researchers at the University of Florida report that the SARS-CoV-2 viroporin triggers the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome, which is responsible for the inflammatory pathology in severely ill COVID-19 patients.

30 Oct 2020

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Researchers generate a transcriptomic map of the COVID brain

COVID-19 is known to be associated with multiple changes in gene expression, but many of these are also seen in chronic brain conditions as well as in some abnormal mental conditions. A recent study published on the preprint server bioRxiv in October 2020 uncovers the molecular basis of this association.

26 Oct 2020

New peptide derivatives that target the SARS-CoV-2 spike protein

In a new study published in the journal Cellular and Molecular Bioengineering, researchers report peptide derivatives, or peptidomimetics, based on the circle residues involved in the interaction of the spike protein and ACE2.

26 Oct 2020

Research uncovers SARS-CoV-2 viral traits critical for the virus in human airways

A new study published on the preprint server bioRxiv* in October 2020 reports the discovery of important viral genomic features that are crucial to its replication in the human airway cells, and its enhancing mutations which increase the rate of replication and determine its target cells.

26 Oct 2020

ACROBiosystems and the Fight Against COVID-19

In this interview, Dr. Yinang Jiang discusses ACROBiosystems and their efforts in the fight against COVID-19 and the search for a vaccine

From ACROBiosystems 23 Oct 2020

DNA vaccine-induced antibodies neutralize SARS-CoV-2

The coronavirus disease (COVID-19) is far from over as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to ravage across the globe. With the vast spread of the virus, many countries who reported flattening the curve over the past months have reported clusters of new cases and second waves of the outbreak.

22 Oct 2020

SARS-CoV-2 mutations dictate severity of COVID-19 disease

A recent study by researchers from Semmelweis University and Pazmany Peter Catholic University in Budapest, Hungary, published on the preprint server medRxiv in October 2020, shows the relationship of specific mutations on the disease's outcome.

22 Oct 2020

Researchers explore effect of temperature on molecular structure of SARS-CoV-2 spike

Didac Martí et al., from the Polytechnic University of Catalonia, in a recent bioRxiv preprint research paper, explore the effect of the temperature on the molecular structure of the SARS-CoV-2 spike glycoprotein. The study specifically focuses on the spike glycoprotein's molecular structural integrity at different temperatures (within 25 ºC and 100 ºC) using atomistic computer simulations.

20 Oct 2020

Researchers apply a novel technique to improve understanding of liver disease, immune activation

Human cells are encased by a membrane coated with diverse sugar molecules known as glycans. These glycans play many roles in health and disease, making them important to understand.

20 Oct 2020

Nanoparticles release bursts of calcium to reverse multidrug resistance in tumor cells

Multidrug resistance (MDR) -- a process in which tumors become resistant to multiple medicines -- is the main cause of failure of cancer chemotherapy.

16 Oct 2020

Researchers discover mechanism that regulates neocortical dendrite development

The research group of Takao Kohno (Nagoya City University) and Mitsuharu Hattori (Nagoya City University), Takahiko Kawasaki (National Institute of Genetics), and Kazunori Nakajima (Keio University School of Medicine) found a new mechanism by which superficial neurons correctly develop their dendrites.

16 Oct 2020

Sanofi Translate Bio MRT5500 COVID-19 vaccine shows promise in preclinical trials

The COVID-19 pandemic is threatening to come back in greater intensity during the winter and fall. Faced with this threat, vaccine development efforts are entering a phase of renewed focus, attempting to identify antigens capable of eliciting protective levels of neutralizing antibodies. A new study published on the preprint server bioRxiv* in October 2020 reports on a novel mRNA vaccine candidate's performance in two animal models.

16 Oct 2020

The COVID-19 vaccine pipeline

Researchers from Mayo Clinic, United States of America, have reviewed the immunity developed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

14 Oct 2020

FDA approves Regeneron antibody drug as first treatment for Ebola virus

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

14 Oct 2020

Glycoprotein News and Research

RNA-binding proteins may suppress antiviral defenses against SARS-CoV-2

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

Evidence of robust and persistent antibodies against SARS-CoV-2

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

SARS-CoV-2 spike D614G variant exhibits enhanced replication and transmissibility

SARS-CoV-2 viroporin triggers NLRP3 inflammasome causing a severe inflammatory response

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

Researchers generate a transcriptomic map of the COVID brain

New peptide derivatives that target the SARS-CoV-2 spike protein

Research uncovers SARS-CoV-2 viral traits critical for the virus in human airways

ACROBiosystems and the Fight Against COVID-19

DNA vaccine-induced antibodies neutralize SARS-CoV-2

SARS-CoV-2 mutations dictate severity of COVID-19 disease

Researchers explore effect of temperature on molecular structure of SARS-CoV-2 spike

Researchers apply a novel technique to improve understanding of liver disease, immune activation

Nanoparticles release bursts of calcium to reverse multidrug resistance in tumor cells

Researchers discover mechanism that regulates neocortical dendrite development

Sanofi Translate Bio MRT5500 COVID-19 vaccine shows promise in preclinical trials

The COVID-19 vaccine pipeline

FDA approves Regeneron antibody drug as first treatment for Ebola virus

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News